Sepetaprost - Santen Pharmaceutical

Drug Profile

Sepetaprost - Santen Pharmaceutical

Alternative Names: DE 126; ONO 9054

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ono Pharmaceutical
  • Developer Ono Pharmaceutical; Santen Pharmaceutical
  • Class Eye disorder therapies; Oxepins; Prostaglandins
  • Mechanism of Action Prostaglandin E EP3 receptor agonists; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ocular hypertension; Open-angle glaucoma

Most Recent Events

  • 08 Aug 2017 Chemical structure information added
  • 25 Jul 2017 Santen initiates the phase IIb Angel trial for Open angle glaucoma and Ocular hypertension in USA (NCT03216902)
  • 11 Jul 2017 Santen plans a phase IIb trial (Angel study) for Open angle glaucoma and Ocular hypertension in USA in July 2017 (NCT03216902)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top